Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea. Its lead product is obeticholic acid, OCA, also known as 6-ethyl-chenodeoxycholic acid or INT-747, marketed as Ocaliva. OCA is a potent first-in-class farnesoid X receptor (FXR) agonist. Ocaliva is approved in the US and the EU for use in primary biliary cholangitis.

Company Growth (employees)
New York, US
Size (employees)
456 (est)
Intercept Pharmaceuticals was founded in 2002 and is headquartered in New York, US

Key People at Intercept Pharmaceuticals

Mark Pruzanski

Mark Pruzanski

Chief Executive Officer & President
Luciano Adorini

Luciano Adorini

Chief Scientific Officer

Intercept Pharmaceuticals Office Locations

Intercept Pharmaceuticals has offices in New York, Wien, Gouda, Mississauga and in 8 other locations
New York, US (HQ)
10 Hudson Yards
Zürich, CH
1 Kalanderpl.
Madrid, ES
135 Paseo de la Castellana
Lisboa, PT
Centro Empresarial Torres de Lisboa Rua Tomás da Fonseca, Torre G, 1º Piso
Milano, IT
6 Largo Francesco Richini
London, GB
2 Pancras Rd
Show all (12)

Intercept Pharmaceuticals Data and Metrics

Intercept Pharmaceuticals Financial Metrics

Intercept Pharmaceuticals's revenue was reported to be $21 m in Q1, 2017

Revenue (Q1, 2017)

21 m

Gross profit (Q1, 2017)

21 m

Gross profit margin (Q1, 2017), %


Net income (Q1, 2017)

(89.9 m)

EBIT (Q1, 2017)

(84 m)

Market capitalization (21-Sep-2017)

1.8 b

Cash (31-Mar-2017)

67 m
Intercept Pharmaceuticals's current market capitalization is $1.8 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


25 m

R&D expense

153.9 m

General and administrative expense

273.6 m

Operating expense total

427.5 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


5.5 m5.2 m21 m

Cost of goods sold

97 k

Gross profit

21 m

Gross profit Margin, %

USDY, 2009Y, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016


4.4 m15.4 m17.7 m45.5 m13.4 m20 m32.7 m43.7 m

Accounts Receivable

9.1 m


2.7 m6.1 m13.6 m2.3 m

Current Assets

147.6 m245.8 m641.7 m707.9 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


45 m18.1 m104.4 m88.3 m72.4 m49.2 m51.7 m105.2 m67 m

Accounts Receivable

10.6 m


2.1 m

Current Assets

306.6 m279.1 m410.4 m741 m702.5 m574.9 m505.3 m794.6 m635 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(67.8 m)(283.2 m)(226.4 m)(412.8 m)

Depreciation and Amortization

105.7 k442.8 k1.7 m3.8 m

Accounts Receivable

(9.1 m)


(1.7 m)(2.3 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

33.5 m(35.8 m)(39.4 m)(47.9 m)(50.9 m)(126.7 m)(77.3 m)(88.8 m)(89.9 m)

Accounts Receivable

10.6 m


2.1 m
USDY, 2017


46.2 k

Financial Leverage

2.8 x
Show all financial metrics

Intercept Pharmaceuticals Market Value History

Traffic Overview of Intercept Pharmaceuticals

Intercept Pharmaceuticals Online and Social Media Presence

Intercept Pharmaceuticals News and Updates

BRIEF-Intercept Pharmaceuticals Q2 net loss per share $3.14

* Intercept pharmaceuticals reports second quarter 2016 financial results and provides business update

Intercept Pharmaceuticals Company Life and Culture

You may also be interested in